Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 31 - 40 records in total 73
    records per page




    Stroke HP Stroke MESHD increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs

    Authors: Vikramjeet Singh; Alexander Beer; Andreas Kraus; Xiaoni Zhang; Jinhua Xue; Dirk M Hermann; Matthias Gunzer

    doi:10.1101/2020.06.24.162941 Date: 2020-06-24 Source: bioRxiv

    BackgroundThe newly emerged severe acute respiratory syndrome coronavirus (SARS-CoV-2 MESHD) has caused a worldwide pandemic of human respiratory disease MESHD. Angiotensin-converting enzyme (ACE) 2 is the key receptor on lung epithelial cells to facilitate initial binding and infection of SARS-CoV-2 MESHD. The binding to ACE2 is mediated via the spike glycoprotein present on the virus surface. Recent clinical data have demonstrated that patients suffering from stroke HP stroke MESHD are particularly susceptible to severe courses of SARS-CoV-2 infection MESHD, thus forming a defined risk group. However, a mechanistic explanation for this finding is lacking. Sterile tissue injuries including stroke HP stroke MESHD induce lymphocytopenia MESHD and systemic inflammation MESHD that might modulate the expression levels of surface proteins in distant organs. Whether systemic inflammation MESHD following stroke HP stroke MESHD can specifically modulate ACE2 expression in the lung has not been investigated. MethodsMice were subjected to transient middle cerebral artery occlusion (MCAO) for 45 min and sacrificed after 24 h and 72 h for analysis of brain and lung tissues. Gene expression and protein levels of ACE2, ACE, IL-6 and IL1{beta} were measured by quantitative PCR and Western blot, respectively. Immune cell populations in lymphoid organs were analyzed by flow cytometry. ResultsStrikingly, 24 h after stroke HP, we observed a substantial increase in the expression of ACE2 both on the transcriptional and protein levels in the lungs of MCAO mice compared to sham-operated mice. This increased expression persisted until day 3 after stroke HP. In addition, MCAO increased the expression of inflammatory cytokines IL-6 and IL-1{beta} in the lungs. Higher gene expression of cytokines IL-6 and IL-1{beta} was found in ischemic brain hemispheres and a reduced number of T-lymphocytes were present in the blood SERO and spleen as an indicator of sterile tissue injury-induced immunosuppression. ConclusionsWe demonstrate significantly augmented ACE2 levels and inflammation in murine lungs after experimental stroke HP. These pre-clinical findings might explain the clinical observation that patients with pre-existing stroke HP represent a high-risk group for the development of severe SARS-CoV-2 infections. Our studies call for further investigations into the underlying signaling mechanisms and possible therapeutic interventions. HighlightsBrain tissue injury increases ACE2 levels in the lungs Brain injury induces pro-inflammatory cytokine expression in the lungs Brain injury causes parenchymal inflammation and systemic lymphopenia HP

    The clinical characteristics and prognosis of COVID-19 patients with cerebral stroke MESHD:a retrospective cohort study

    Authors: Xiaolong Yao; Shengwen Liu; Junwen Wang; Kai Zhao; Xiaobing Long; Xuejun He; Huicong Kang; Yiping Yang; Xiaopeng Ma; Pengjie Yue; Kai Shu; Zhouping Tang; Ting Lei; Jihong Liu; Wei Wang; Huaqiu Zhang

    doi:10.21203/rs.3.rs-37573/v1 Date: 2020-06-23 Source: ResearchSquare

    Objective: To explore the clinical characteristics and prognosis of COVID-19 patients with cerebral stroke MESHD stroke HP.Methods: In this retrospective study, 2474 patients with COVID-19 were admitted and treated in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan from February 10, 2020, to March 24, 2020. Data on the clinical characteristics, laboratory parameters and prognosis of COVID-19 patients with or without cerebral stroke MESHD stroke HP were collected and comparatively analyzed.Results: Of 2474 COVID-19 patients (61.0±15.7 years; 1235 males TRANS [49.9%]), 113 (4.7%) patients had cerebral stroke MESHD stroke HP, and 25 (1.0%) patients had a new onset of stroke HP stroke MESHD. Eighty-eight (77.9%) patients in the previous stroke HP stroke MESHD group had cerebral ischemia HP cerebral ischemia MESHD, while 25 (22.1%) patients in the new-onset stroke HP stroke MESHD group had cerebral ischemia HP cerebral ischemia MESHD. Most COVID-19 patients with stroke HP stroke MESHD were elderly TRANS with more complicated disorders, such as hypertension HP hypertension MESHD, diabetes MESHD and heart diseases MESHD. Laboratory examinations showed a hypercoagulation status MESHD and elevated serum SERO parameters such as IL-6, cTnI, NT pro-BNP and BUN. Of note, stroke HP stroke MESHD patients revealed a nearly double mortality (12.4% vs 6.9%) to that of patients without stroke HP stroke MESHD. Additionally, age TRANS (≥60 years), fingertip oxygen saturation (<93%) and consciousness disorder MESHD were independent predictors for new cerebral stroke MESHD stroke HP in COVID-19 patients. Interpretation: The high risk of new-onset stroke HP stroke MESHD in COVID-19 patients was older age TRANS combined with fingertip oxygen saturation (<93%) and consciousness disorder MESHD. These patients are more vulnerable to multiple organ dysfunction MESHD and an overactivated inflammatory response, in turn leading to a deteriorated outcome and mortality.

    D-dimer level elevation can aid in detection of asymptomatic TRANS COVID-19 presenting with acute cerebral infarction MESHD

    Authors: Takeru Umemura; Hirohisa Kondo; Hirotsugu Ohta; Koichiro Futatsuya; Takamitsu Mizobe

    doi:10.21203/rs.3.rs-36445/v1 Date: 2020-06-19 Source: ResearchSquare

    Coronavirus disease 2019 (COVID-19) mainly manifests as a respiratory syndrome MESHD, besides causing other complications. Severe COVID-19 may also present with coagulopathy MESHD, leading to venous thrombosis and cerebral HP venous thrombosis and cerebral MESHD cerebral infarction MESHD. Stroke HP Stroke MESHD is one of the complications associated with severe COVID-19. Generally, acute stroke MESHD stroke HP is the second complication in patients with respiratory syndrome MESHD. Here, we present a case of COVID-19 in an 84-year-old female TRANS patient who did not manifest any respiratory symptoms; however, she presented with acute stroke MESHD stroke HP. The patient had no cough HP cough MESHD or fever HP fever MESHD before the stroke HP stroke MESHD onset, but the COVID-19 PCR was positive. The patient also had markedly elevated D-dimer levels. Our findings suggest that coagulopathy MESHD can occur, even in a patient with asymptomatic TRANS COVID-19 infection MESHD. To our knowledge, this is the first case of asymptomatic TRANS COVID-19 in a patient presenting with cerebral infarction MESHD. We concluded that elevation of D-dimer levels is one of the tools to ascertain COVID-19 infection MESHD in such patients.

    Association of hypertension HP hypertension MESHD, diabetes MESHD, stroke HP stroke MESHD, cancer MESHD, kidney disease MESHD, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review

    Authors: Nazar Zaki; Hany Alashwal; Sahar Ibrahim

    doi:10.1101/2020.06.16.20132639 Date: 2020-06-19 Source: medRxiv

    Objective: To undertake a review and critical appraisal of published/preprint reports that offer methods of determining the effects of hypertension HP hypertension MESHD, diabetes MESHD, stroke HP stroke MESHD, cancer MESHD, kidney issues, and high-cholesterol on COVID-19 disease severity. Data sources: Google Scholar, PubMed, COVID-19 Open Research Dataset: a resource of over 128,000 scholarly articles, including over 59,000 articles with full text related to COVID-19, SARS-CoV-2, and coronaviruses. Methods: A search was conducted by two authors independently on the freely available COVID-19 Open Research Dataset (CORD-19). We developed an automated search engine to screen a total of 59,000 articles in a few seconds. The search engine was built using a retrieval function that ranks a set of documents based on the query terms appearing in each document regardless of their proximity within the document. Filtering of the articles was then undertaken using keywords and questions, e.g. "Effects of diabetes MESHD on COVID/normal coronavirus/SARS-CoV-2/nCoV/COVID-19 disease severity, mortality?". The search terms were repeated for all the comorbidities considered in this paper. Additional articles were retrieved by searching via Google Scholar and PubMed. Findings: A total of 54 articles were considered for a full review. It was observed that diabetes MESHD, hypertension HP hypertension MESHD, and cholesterol levels possess an apparent relation to COVID-19 severity. Other comorbidities, such as cancer MESHD, kidney disease MESHD, and stroke HP stroke MESHD, must be further evaluated to determine a strong relationship to the virus. Reports associating cancer MESHD, kidney disease MESHD, and stroke HP stroke MESHD with COVID-19 should be carefully interpreted, not only because of the size of the samples, but also because patients could be old, have a history of smoking, or have any other clinical condition suggesting that these factors might be associated with the poor COVID-19 outcomes rather than the comorbidity itself. Such reports could lead many oncologists and physicians to change their treatment strategies without solid evidence and recommendations. Further research regarding this relationship and its clinical management is warranted. Additionally, treatment options must be examined further to provide optimal treatment and ensure better outcomes for patients suffering from these comorbidities. It should be noted that, whether definitive measurements exist or not, the care of patients as well as the research involved should be largely prioritized to tackle this deadly pandemic.

    Impact of COVID-19 on Neurological Manifestations: An Overview of Stroke HP Stroke MESHD Presentation in Pandemic.

    Authors: Nida Fatima; Maher Saqqur; Ashfaq Shauib

    doi:10.21203/rs.3.rs-36387/v1 Date: 2020-06-18 Source: ResearchSquare

    Introduction: Corona virus disease 2019 (COVID-19) pandemic has become a globally challenging issue after its emergence in December 2019 from Wuhan, China. Despite its common presentation as respiratory distress HP, patients with COVID-19 have also shown neurological manifestation especially stroke HP stroke MESHD. Therefore, the authors sought to determine the etiology, underlying risk factors, and outcomes among patients with COVID-19 presenting with stroke HP stroke MESHD. Methods: We conducted a systematic review of the electronic database (PubMed, Google Scholar, Scopus, Medline, EMBASE, and Cochrane library) using different MeSH terms from January 2000 to June 2020. Results: A total of 39 patients with stroke HP stroke MESHD from 6 studies were included. The mean age TRANS of our included patients was 61.4±14.2 years. Majority of the patients (92.3%) with COVID-19 had ischemic stroke HP ischemic stroke MESHD, 5.1% had hemorrhagic stroke MESHD stroke HP, and 2.6% had cerebral venous thrombosis HP cerebral venous thrombosis MESHD at the time of initial clinical presentation. Almost all of the patients presented had underlying risk factors predisposing to stroke HP stroke MESHD which included, diabetes mellitus HP diabetes mellitus MESHD, hyperlipidemia HP hyperlipidemia MESHD, hypertension HP hypertension MESHD, and previous history of cerebrovascular disease MESHD. 51.2% of the included patients infected with COVID-19 with stroke HP stroke MESHD died, while remaining patients were either discharged home or transferred to a rehabilitation unit.  Conclusion: Exploring the neurological manifestation in terms of stroke HP stroke MESHD among patients with COVID-19 is a step towards better understanding of the virus, preventing further spread, and treating the patients affected by this pandemic.

    Neurological Complications of COVID-19: A Systematic Review of Literature

    Authors: Shitiz Sriwastava; Samiksha Srivastava; Saurabh Kataria; Violina Melnic; Amelia Adcock; Zubeda Sheikh

    doi:10.21203/rs.3.rs-35507/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To study the nature and frequency of occurrence of “significant” neurological complications MESHD in coronavirus disease-2019 (COVID-19) via a systematic review of the literature.Methods: We screened all articles resulting from a search of PubMed, Cochrane, Google Scholar and Scopus, using the keywords "COVID-19 and CNS", "SARS-CoV-2 and CNS”, “COVID-19 and neurological manifestation”, “SARS2 and neurological manifestation” and “COVID-19 and Brain” looking for reports of significant neurological manifestations that would potentially have an impact on the outcome.Results: Twenty-six articles met the inclusion criteria. The significant neurological diagnoses reported were stroke HP stroke MESHD, Guillain Barre Syndrome MESHD ( GBS MESHD) and its variants, encephalitis HP encephalitis MESHD, seizures HP seizures MESHD, acute hemorrhagic necrotizing encephalopathy MESHD necrotizing encephalopathy, acute HP acute disseminated encephalomyelitis MESHD ( ADEM MESHD) and transverse myelitis HP myelitis MESHD. Although stroke HP stroke MESHD, predominantly ischemic MESHD, was observed in ~ 6% of COVID-19 patients from Wuhan, China, mortality in this cohort was 38%. Of the 24 pooled patients with reports of etiology, 17 had large vessel occlusions. GBS MESHD occurred in 5/1200 (0.4%) of the COVID-19 cohort from Italy. One of the six reported encephalitis HP encephalitis MESHD cases, the ADEM MESHD case and the report of transverse myelitis HP myelitis MESHD do not have data for conclusive diagnosis.Conclusion: The most frequent significant neurological association with COVID-19 is stroke HP stroke MESHD, predominantly ischemic MESHD. In a cohort from Wuhan, China, this was as frequent as ~ 6%, with a 38% mortality. Most common reported etiology is large vessel occlusion. Other reported significant neurological complications are GBS MESHD/variants, encephalitis HP encephalitis MESHD, seizures HP seizures MESHD and acute hemorrhagic necrotizing encephalopathy MESHD necrotizing encephalopathy HP. The reports of ADEM MESHD and transverse myelitis HP myelitis MESHD lacked diagnostically conclusive data.

    No Evidence for Reduced Hospital Admissions or Increased Deaths from Stroke HP Stroke MESHD or Heart Attack During COVID-19

    Authors: Katharine Reeves; Samuel I Watson; Tanya Pankhurst; Kamlesh Khunti; Suzy Gallier; Magdalena Skrybant; Peter J Chilton; Richard J Lilford

    doi:10.1101/2020.06.08.20119636 Date: 2020-06-09 Source: medRxiv

    Articles in the UK press have claimed that hospital admissions for heart attack and stroke HP stroke MESHD have declined during the COVID-19 pandemic. However, data from the West Midlands Ambulance Service have not shown any reduction in call-outs for patients with stroke HP stroke MESHD or ST-Elevation Myocardial Infarction HP Myocardial Infarction MESHD. This study examined data from University Hospital Birmingham NHS Foundation Trust, comparing admissions from week 1 of 2016 to week 17 of 2019, with the same period in 2020, pre- and post-lockdown. The results showed that there was no evidence of a reduction in the overall mean number of admissions of patients with these conditions in the post-lockdown period.

    Cytokine Release Syndrome-Associated Encephalopathy MESHD Encephalopathy HP in Patients with COVID-19

    Authors: Peggy Perrin; Nicolas Collongues; Seyyid Baloglu; Dimitri Bedo; Xavier Bassand; Thomas Lavaux; Gabriela Gautier; Nicolas Keller; Stephane Kremer; Samira Fafi-Kremer; Bruno Moulin; Ilies Benotmane; Sophie Caillard

    id:10.20944/preprints202006.0103.v1 Date: 2020-06-07 Source: Preprints.org

    Severe disease MESHD and uremia MESHD are risk factors for neurological complications of coronavirus disease MESHD-2019 (COVID-19). An in-depth analysis of a case series was conducted to describe the neurological manifestations of patients with COVID-19 and gain pathophysiological insights that may guide clinical decision-making – especially with respect to the cytokine release syndrome (CRS). Extensive clinical, laboratory, and imaging phenotyping was performed in five patients. Neurological presentation included confusion HP confusion MESHD, tremor HP tremor MESHD, cerebellar ataxia MESHD ataxia HP, behavioral alterations, aphasia HP aphasia MESHD, pyramidal syndrome, coma HP coma MESHD, cranial nerve palsy MESHD, dysautonomia MESHD, and central hypothyroidism HP hypothyroidism MESHD. Neurological disturbances MESHD were remarkably accompanied by laboratory evidence of CRS. SARS-CoV-2 was undetectable in the cerebrospinal fluid. Hyperalbuminorachy and increased levels of the astroglial protein S100B were suggestive of blood SERO-brain barrier (BBB) dysfunction. Brain MRI findings comprised evidence of acute leukoencephalitis MESHD (n = 3, of whom one with a hemorrhagic form), cytotoxic edema HP edema MESHD mimicking ischemic stroke HP ischemic stroke MESHD (n = 1), or normal results (n = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted – resulting in rapid recovery from neurological disturbances MESHD in two cases. Patients with COVID-19 can develop neurological manifestations that share clinical, laboratory, and imaging similarities with those of chimeric antigen receptor-T cell-related encephalopathy HP encephalopathy MESHD. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune-mediated mechanisms.

    ACUTE VISION LOSS IN A MESHD PATIENT WITH COVID-19

    Authors: Vijairam Selvaraj; Daniel Sacchetti; Arkadiy Finn; Kwame Dapaah-Afriyie

    doi:10.1101/2020.06.03.20112540 Date: 2020-06-05 Source: medRxiv

    To date, there have been reports of neurologic manifestations in Covid-19 patients including ischemic strokes HP ischemic strokes MESHD, Guillain-Barre Syndrome MESHD and anosmia HP anosmia MESHD. In this case report, we report a patient who presented with dysosmia MESHD, dysgeusia MESHD along with monocular peripheral vision loss MESHD after being diagnosed with Covid-19.

    Reduction in stroke HP stroke MESHD patients' referral to the ED in the COVID-19 era: A four-year comparative study

    Authors: Mor Saban; Anna Reznik; Tal Shachar; Rotem Sivan-Hoffmann III

    doi:10.1101/2020.05.30.20118125 Date: 2020-06-03 Source: medRxiv

    Abstract Introduction. Current reports indicate that the increased use of social distancing for preventive COID-19 distribution may have a negative effect on patients who suffering from acute medical conditions. Aim. We examined the effect of social distancing on acute ischemic stroke HP ischemic stroke MESHD ( AIS MESHD) patients' referral to the emergency department (ED) Method. A retrospective archive study was conducted between January 2017 and April 2020 in a comprehensive stroke HP stroke MESHD center. We compare the number of neurologic consultations, time from symptoms onset TRANS to ED arrival, patients diagnosis with AIS MESHD, number of patients receiving treatment (tPA, endovascular thrombectomy (EVT) or combine) and in-hospital death. Results. The analysis included a total of 14,626 neurological consultations from the years 2017 to 2020. A significant decrease of 58.6% was noted during the months of January-April of the year 2020 compared to the parallel period of 2017. Percent of final AIS diagnosis for the year of 2020 represent 24.8% of suspected cases, with the highest diagnosis rate demarcated for the year of 2019 with 25.6% of confirmed patients. The most remarkable increase was noted in EVT performance SERO through the examined years (2017, n=21; 2018, n=32; 2019, n=42; 2020, n=47). Conclusion. COVID-19 pandemic resulted in routing constraints on health care system resources that were dedicated for treating COVID-19 patients. The healthcare system must develop and offer complementary solutions that will enable access to health services even during these difficult times.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.